Literature DB >> 7389058

Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study.

G Bolis, G Bortolozzi, G Carinelli, M D'Incalci, F Gramellini, L Morasca, C Mangioni.   

Abstract

After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7389058     DOI： 10.1007/bf00254034

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

1.  Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer.

Authors:  C Mangioni; G Bolis; N Natale; L Morasca
Journal:  Eur J Cancer       Date:  1976-05       Impact factor: 9.162

2.  Randomized study of chemoimmunotherapy for advanced ovarian carcinoma: a preliminary report of a Southwest Oncology Group study.

Authors:  D S Alberts; T E Moon; R A Stephens; H Wilson; N Oishi; R D Hilgers; R O'Toole; J T Thigpen
Journal:  Cancer Treat Rep       Date:  1979-02

3.  Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease.

Authors:  J H Edmonson; T R Fleming; D G Decker; G D Malkasian; E O Jorgensen; J A Jefferies; M J Webb; L K Kvols
Journal:  Cancer Treat Rep       Date:  1979-02

4.  Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.

Authors:  G M de Palo; M de Lena; F Di Re; L Luciani; P Valagussa; G Bonadonna
Journal:  Surg Gynecol Obstet       Date:  1975-12

5.  Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.

Authors:  C T Griffiths
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

6.  Prognostic importance of histologic grading in ovarian carcinoma.

Authors:  D G Decker; G D Malkasian; W F Taylor
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

7.  Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial.

Authors:  R E Lloyd; S E Jones; S E Salmon; B G Durie; L J McMahon
Journal:  Cancer Treat Rep       Date:  1976-01

8.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

Authors:  R C Young; B A Chabner; S P Hubbard; R I Fisher; R A Bender; T Anderson; R M Simon; G P Canellos; V T DeVita
Journal:  N Engl J Med       Date:  1978-12-07       Impact factor: 91.245

9.  The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).

Authors:  S E Vogl; M Berenzweig; B H Kaplan; M Moukhtar; W Bulkin
Journal:  Cancer Treat Rep       Date:  1979-02

10.  Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide.

Authors:  R C Young; G P Canellos; B A Chabner; P S Schein; S P Hubbard; V T DeVita
Journal:  Gynecol Oncol       Date:  1974-12       Impact factor: 5.482
View more
  8 in total

1.  Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Authors:  Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana
Journal:  Clin Cancer Res       Date:  2012-11-08       Impact factor: 12.531

Review 2.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

3.  Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults.

Authors:  Jessica Bodea; Kenneth J Caldwell; Sara M Federico
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

4.  A study of the treatment of ovarian carcinoma.

Authors:  H Pickel
Journal:  Arch Gynecol       Date:  1983

5.  Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.

Authors:  C Sessa; G Bolis; N Colombo; M D'Incalci; B Mermillod; I Valente; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12

7.  Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

Authors:  S Marsoni; V Torri; M G Valsecchi; C Belloni; U Bianchi; G Bolis; C Bonazzi; N Colombo; A Epis; G Favalli
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

8.  Dose intensity analysis in advanced ovarian cancer patients.

Authors:  V Torri; E L Korn; R Simon
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.